Prediction of site-specific pharmacologic therapy among newborns with neonatal opioid withdrawal syndrome

Authors:
  • ENEunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network and the NIH Environmental Influences on Child Health Outcomes (ECHO) Program Institutional Development Awards States Pediatric Clinical Trials Networ
    Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network and the NIH Environmental Influences on Child Health Outcomes (ECHO) Program Institutional Development Awards States Pediatric Clinical Trials Networ

Abstract
Objective To predict pharmacotherapy for NOWS based on factors available shortly after birth. Study design A multi-center, retrospective study of 1377 opioid exposed newborns between 2016 and 2017 dichotomized based on pharmacologic treatment (N = 665 treated, N = 712 not treated) was conducted. A multilevel mixed-effect logistic regression model that considered cluster effect from sites determined significant maternal and newborn factors associated with pharmacotherapy, which were combined in a nomogram to predict probability of treatment for infants at each participating site. Results Factors predictive of treatment were: no breastmilk (1.76, 1.30–2.39; p < 0.001), male sex (1.39, 1.05–1.83; p = 0.021), polysubstance exposure (1.53, 1.15–2.06; p = 0.004), inadequate prenatal care (1.51, 1.07–2.13; p < 0.018) and Methadone (6.08, 4.03–9.27; p < 0.001) or Buprenorphine (1.86, 1.29–2.69; p < 0.001). A site-specific nomogram provided the probability of treatment for individual newborns. Conclusion Six factors available shortly after birth can be combined to predict site-specific use of medication for NOWS. If confirmed, the nomogram may identify at-risk newborns.

This publication has 34 references indexed in Scilit: